CFT7455 CAS:2504235-67-8 is an anticancer agent with orally active zinc finger transcription factor (IKZF1) (Ikaros) and IKZF3 (Aiolos) degrader.
CFT7455 is a novel anti-cancer agent that has been designed to selectively bind to cereblon, an E3 ubiquitin ligase that plays a critical role in the regulation of protein turnover and cell cycle progression. The molecule contains several functional groups, including a pyrimidine ring, a phenyl group, and a carboxylic acid moiety, which are essential for its binding affinity and pharmacological activity.
In recent years, CFT7455 has emerged as a promising candidate for the treatment of various forms of cancer, including multiple myeloma, lymphoma, and solid tumors. Its high affinity for cereblon enables it to induce the degradation of specific target proteins, such as Ikaros and Aiolos transcription factors, leading to the inhibition of cancer cell proliferation and survival.
In addition to its therapeutic potential, CFT7455 has also been utilized as a tool compound in pharmaceutical research and development. Its specific binding to cereblon and subsequent degradation of target proteins has provided valuable insights into the underlying mechanisms of cancer biology and has facilitated the identification of new drug targets and therapeutic strategies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.